Description

Mesenchymal stem cells (MSCs) are currently used in several pre-clinical and clinical studies to support hematopoiesis after hematopoietic stem cell transplantation (HSCT), to control graft versus host disease after allogeneic HSCT or for gene therapy in cancer. MSCs give rise to bone marrow (BM) stromal cells that interact with myeloma cells and some recent studies revealed that MSCs in myeloma patients might be different from those in normal individuals. In this project we aim to examine at which level MSCs affect tumor growth and bone disease in Multiple Myeloma (MM). We aim to examine whether MM-BM MSCs express aberrant features and whether these abnormalities are MM-cell induced or intrinsic. We will also test the effect of new MM drugs (proteasome and histone deacetylase (HDAC) inhibitors) on MM-BM MSCs. At last we will examine in an in vivo mouse model whether normal (donor-derived) MSCs can be used as an efficient and safe cellular vehicle to deliver tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to MM cells in the BM microenvironment.
AcronymADSI233
StatusFinished
Effective start/end date1/10/1031/12/11

    Research areas

  • Stem Cell, Blood, Coagulation, Myeloma, Immunology, Microbiology, HLA, Hematology, Lymphoma, cancer, Bone Marrow Transplantation

    Flemish discipline codes

  • Basic sciences
  • Biological sciences

ID: 3354340